Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)

被引：0
|
作者：
Hernando Cubero, J. [1 ]
Taberna Sanz, M. [2 ]
Carmona Bayonas, A. [3 ]
Iglesias, L. [4 ]
Grande, E. [5 ]
Trigo Perez, J. M. [6 ]
Grau, J. J. [7 ]
Lopez-Picazo, J. M. [8 ]
Castelo, B. [9 ]
Alonso Gordoa, T. [10 ]
Lorenzo, I. [11 ]
Casado Herraez, A. [12 ]
Ugidos, L. [13 ]
Munarriz, J. [14 ]
Lavernia, J. [15 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[2] Hosp Duran & Reynals, ICO, Med Oncol, Lhospitalet De Llobregat, Spain
[3] Hosp Univ Morales Meseguer, Hematol & Med Oncol, Murcia, Spain
[4] Univ Hosp 12 Octubre, Oncol, Madrid, Spain
[5] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
[6] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
[7] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[8] Clin Univ Navarra, Med Oncol, Pamplona, Spain
[9] Hosp Univ La Paz, Med Oncol, Madrid, Spain
[10] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain
[11] Complejo Hosp Univ Vigo, Med Oncol, Vigo, Spain
[12] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
[13] HM San Chinarro, Med Oncol, Madrid, Spain
[14] Hosp Gen Castellon, Med Oncol, Castellon de La Plana, Spain
[15] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1872TiP
引用
收藏
页码：759 / 759
页数：1
相关论文
共 50 条
  • [41] Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial
    Marandino, L.
    Raggi, D.
    Giannatempo, P.
    Calareso, G.
    Alessi, A.
    Colecchia, M.
    Madison, R.
    Ross, J. S.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S595 - S595
  • [42] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial (vol 21, pg 1574, 2020)
    Powles, T.
    van der Heijden, M. S.
    Castellano, D.
    LANCET ONCOLOGY, 2021, 22 (01): : E5 - E5
  • [43] UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma -: A multiinstitutional Phase II trial
    Ichinose, Y
    Yosimori, K
    Yoneda, S
    Kuba, M
    Kudoh, S
    Niitani, H
    CANCER, 2000, 88 (02) : 318 - 323
  • [44] Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) plus /- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
    Leary, A.
    Rouge, T. De La Motte
    Lortholary, A.
    Asselain, B.
    Alexandre, J.
    Floquet, A.
    Savoye, A. M.
    Chardin, L.
    Delanoy, N.
    Gavoille, C.
    You, B.
    D'Hondt, V.
    Grenier, J.
    Genestie, C.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S731 - S731
  • [45] A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
    Abou-Alfa, G. K.
    Fan, J.
    Heo, J.
    Arai, Y.
    Erinjeri, J. P.
    Kuhl, C. K.
    Lencioni, R.
    Ren, Z.
    Zeng, A.
    Evans, B.
    Cohen, G.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S874 - S874
  • [46] Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial
    Mesia, R.
    Rueda, A.
    Vera, R.
    Lozano, A.
    Medina, J. A.
    Aguiar Bujanda, D., III
    Arias de la Vega, F.
    Triana, G.
    Guix, M.
    Lopez, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Individualized cancer treatment based on molecular profiling of circulating tumor DNA in patients with advanced and refractory carcinoma: a prospective phase II trial
    Riedl, J.
    Perakis, S.
    Pregartner, G.
    Scheipner, L.
    Posch, F.
    Groller, K.
    Kashofer, K.
    Jahn, S. W.
    Bauernhofer, T.
    Pichler, M.
    Stoeger, H.
    Berghold, A.
    Hoefler, G.
    Speicher, M.
    Heitzer, E.
    Gerger, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 249 - 249
  • [48] Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
    Giannatempo, P.
    Bottiglieri, A.
    Guadalupi, V.
    Marandino, L.
    Raggi, D.
    Stellato, M.
    Rametta, A.
    Baciarello, G.
    Sepe, P.
    Claps, M.
    Buti, S.
    Pipitone, S.
    Iacovelli, R.
    Calareso, G.
    Alessi, A.
    Cattaneo, L.
    Verzoni, E.
    Ortega, C.
    Procopio, G.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1205 - S1205
  • [49] First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S)
    Abou-Alfa, Ghassan K.
    Capanu, Marinela
    Do, Richard Kinh Gian
    Hollywood, Ellen
    Ly, Michele
    Chou, Joanne F.
    Lee, Jean Kyung
    Connell, Louise Catherine
    Wan, Peter Justin
    Bradley, Margaret
    Harding, James J.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center trial TRC-0301
    Chen, Helen X.
    Mooney, Margaret
    Boron, Matthew
    Vena, Don
    Mosby, Kimberly
    Grochow, Louise
    Jaffe, Carl
    Rubinstein, Lawrence
    Zwiebel, James
    Kaplan, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) : 3354 - 3360
12345